Wire · opportunities
FDA Approves 2 gMG Treatments, AR1001 Slows Decline in Monotherapy Group ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA approved two new treatments for adults with acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG), gefurulimab and cemdisiran, expanding patient treatment options. Additionally, the phase 3 POLARIS-AD trial showed AR1001 slowed clinical decline in the monotherapy population with early Alzheimer's disease.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have new treatment options for generalized myasthenia gravis that offer distinct dosing schedules and mechanisms. Alzheimer's drug developers must note AR1001's promise in early monotherapy, signalling a niche to target amid broader trial challenges.
◆ Coverage
1 source · 21 Nov 2026
◆ Related on Wire
◆ Topics